⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
High cost outlier (population + peer)
Risk indicators are statistical patterns, not allegations. Learn more
2,752
Total Claims
$2.7M
Drug Cost
296
Beneficiaries
$9,113
Cost/Patient
Risk Score Breakdown 6/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+6
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+132%
Cost per patient vs peers
$9,113 vs $3,933 avg
-5%
Brand preference vs peers
48.6% vs 51.2% avg
Brand vs Generic
51% generic
Brand: 1,266 claims · $2.7M
Generic: 1,338 claims · $27K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Asfotase Alfa | 12 | $1.6M |
| Dulaglutide | 104 | $164K |
| Semaglutide | 121 | $159K |
| Empagliflozin | 125 | $135K |
| Insulin Aspart | 49 | $54K |
| Sitagliptin Phosphate | 51 | $47K |
| Dapagliflozin Propanediol | 38 | $47K |
| Insulin Degludec | 32 | $42K |
| Insulin Lispro | 37 | $33K |
| Insulin Lispro | 35 | $33K |
| Insulin Aspart | 13 | $31K |
| Insulin Glargine,hum.Rec.Anlog | 48 | $29K |
| Levothyroxine Sodium | 261 | $25K |
| Insulin Detemir | 35 | $22K |
| Exenatide Microspheres | 17 | $21K |
Prescribing Profile
Patient Profile
72
Avg Age
65%
Female
1.29
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About